457639-26-8

Usage

Biochem/physiol Actions

Celecoxib, and the inactive analog 2′,5′-dimethyl celecoxib both induce apoptosis in a many cancer cell lines by down-regulating the expression of survivin. This activiy is mediated via an AKT mediated pathway, and is unique to this class of cyclo-oxygenase inhibitors, as non-selective NSAIDs or other COX-2 specific inhibitors such as rofecoxib, do not effect survivin expression. Unlike celecoxib, 2′,5′-dimethyl celecoxib is devoid of any inhibitory activity against COX-2.

Downstream Products

• 1383381-41-6 4-(bis-N,N’-4-isopropylidene cyclohex-1-enylmethyloxycarbonyl[5-(2,5-dimethylphenyl)-3-trifluoromethylpyrazol-1-yl]benzenesulfonamide) 

Relevant academic research and scientific papers

1,5-diarylpyrazole derivative, and synthetic method and application thereof

The invention relates to a 1,5-diaryl pyrazole derivative and antibacterial application thereof. On the basis of a celecoxib structure, structural modification is conducted on 1,5-diaryl to obtain the 1,5-diaryl pyrazole derivative; and after structural c

Compounds and methods for inducing apoptosis in proliferating cells

Compounds useful for inducing apoptosis in proliferative cells, particularly cancer cells, including but not limited to prostate cancer, leukemia, non-smalll cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, bladder cancer, lymphoma, and breast cancer. These compounds are particularly useful in the treatment of androgen-independent cancers, including hormone-refractory prostate cancer. Further provided are methods of treating cancer in a subject in need of such treatment using the compounds of the present invention. Further provided are methods for using the compounds of the present invention to treat, inhibit, or delay the onset of cancer in a subject. Further provided are methods of inducing apoptosis in rapidly proliferating cells, particularly, though not necessarily cancer cells, using the compounds of the present invention.